Alnylam Pharma (ALNY) Tops Q4 EPS by 46c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $229.30 -5.49%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.39), $0.46 better than the analyst estimate of ($1.85). Revenue for the quarter came in at $335.04 million versus the consensus estimate of $312.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
- Largo restructures $82.2M in debt, extending maturity to 2030
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
